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Rationale: The new acronym, PES pathogens (Pseudomonas aeruginosa, Enterobacteriaceae extended-
spectrum beta-lactamase-positive, and methicillin-resistant Staphylococcus aureus), was recently pro-
posed to identify drug-resistant pathogens associated with community-acquired pneumonia.
Objectives: To evaluate the risk factors for antimicrobial-resistant pathogens in immunocompetent pa-
tients with pneumonia and to validate the role of PES pathogens.
Methods: A retrospective analysis of a prospective observational study of immunocompetent patients
with pneumonia between March 2009 and June 2015 was conducted. We clariﬁed the risk factors for PES
pathogens.
Results: Of the total 1559 patients, an etiological diagnosis was made in 705 (45.2%) patients. PES
pathogens were identiﬁed in 51 (7.2%) patients, with 53 PES pathogens (P. aeruginosa, 34; ESBL-positive
Enterobacteriaceae, 6; and MRSA, 13). Patients with PES pathogens had tendencies toward initial treat-
ment failure, readmission within 30 days, and a prolonged hospital stay. Using multivariate analysis,
female sex (adjusted odds ratio [AOR] 1.998, 95% conﬁdence interval [CI] 1.047e3.810), admission within
90 days (AOR 2.827, 95% CI 1.250e6.397), poor performance status (AOR 2.380, 95% CI 1.047e5.413), and
enteral feeding (AOR 5.808, 95% CI 1.813e18.613) were independent risk factors for infection with PES
pathogens. The area under the receiver operating characteristics curve for the risk factors was 0.66 (95%
CI 0.577e0.744).
Conclusions: We believe the deﬁnition of PES pathogens is an appropriate description of drug-resistant
pathogens associated with pneumonia in immunocompetent patients. The frequency of PES pathogens is
quite low. However, recognition is critical because they can cause refractory pneumonia and different
antimicrobial treatment is required.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese Society of Chemotherapy and The
Japanese Association for Infectious Diseases. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pneumonia caused by drug-resistant pathogens (DRPs) has
traditionally been conﬁned to hospital-acquired pneumonia. In
recent years, resistant pathogens have extended into the commu-
nity because of developed healthcare delivery and treatment. In
2005, in the joint guidelines proposed by the American Thoracicpital (1-1-1, Miwa, Kurashiki,
edicine, Kurashiki Central
are Foundation, 1-1-1, Miwa,
2 6696.
onbehalf of Japanese SocietyofChem
org/licenses/by-nc-nd/4.0/).Society (ATS) and the Infectious Disease Society of America (IDSA),
a new category of pneumonia, healthcare-associated pneumonia
(HCAP) was deﬁned [1]. The original ATS/IDSA guidelines stated
that all patients with HCAP should receive empiric antimicrobial
treatment directed at DRPs. However, some limitations have arisen
regarding the deﬁnition of HCAP, including the following: some of
the variables differ between countries; variables predict different
multidrug-resistant pathogens (MDRs); and the concept of HCAP
could lead to overtreatment in some cases [2,3].
Recently, Prima and colleagues have proposed the acronym PES
(Pseudomonas aeruginosa, Enterobacteriaceae extended-spectrum
beta-lactamase-positive, and methicillin resistant Staphylococcus
aureus) which require different treatments when identiﬁed in
community-acquired pneumonia (CAP), including nursingotherapyandThe JapaneseAssociation for InfectiousDiseases. This is anopenaccess article
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PES pathogens.
The aim of this study was to evaluate PES pathogens in immu-
nocompetent patients with pneumonia by comparing clinical
characteristics and outcomes with immunocompetent patients
who had no PES pathogens and to subsequently identify the risk
factors for PES pathogens in our patients.
2. Materials and methods
2.1. Study population and data collection
We conducted a retrospective analysis of a prospective obser-
vational study of immunocompetent patients over 16 years of age
with pneumonia who were admitted to the Kurashiki Central
Hospital (1150-bed-community hospital) between March 2009 and
June 2015. The study was approved by the Kurashiki Central Hos-
pital ethics committee. Informed consent was obtained from all of
the patients at the time of admission.
Pneumonia was diagnosed by the presence of new inﬁltrative
shadows on chest x-rays and symptoms such as acute respiratory
infection including cough, fever, purulent sputum, dyspnea, and
chest pain. We excluded patients with hospital-acquired pneu-
monia; those who had previously used corticosteroids (10 mg
prednisolone-equivalent/day); those who had undergone immu-
nosuppressive therapy; and those who had active neoplasms, hu-
man immunodeﬁciency virus infection, or active tuberculosis.
Residents of nursing homes or extended-care facilities were
included when they were thought to be immunocompetent.
Baseline demographic and clinical data was obtained from all
patients upon admission. Data included patient characteristics (age,
sex, smoking history, alcohol consumption, nursing home resi-
dency, comorbid diseases, previously used antimicrobials, enteral
feeding, and performance status by the Eastern Cooperative
Oncology Group criteria [5]) in addition to vital signs, pneumonia
severity, laboratory data, percutaneous oxygen saturation or arte-
rial blood gases, chest roentgenograms, microbiological examina-
tions, previously used antimicrobials, and clinical outcomes.
The outcome measures were 30-day survival or hospital
discharge within 30 days. Initial treatment failure was deﬁned as
death during initial treatment or a change in antimicrobial treat-
ment due to poor response to initial therapy. Recurrence was
deﬁned as emergence of pneumonia after remission of a prior case.
The pneumonia severity index system [6] was used to evaluate
pneumonia severity.
All of the variables were compared between patients with PES
pathogens and those with non-PES pathogens.
2.2. Microbiological examination
Blood cultures were performed on all patients upon admission.
If sputum was available, Gram staining and quantitative cultures
were performed. Sputum data was evaluated when Gram staining
revealed numerous leukocytes (>25 in a 100X microscopic ﬁeld)
but few epithelial cells. An organism exhibiting heavy growth (107
colony forming units [CFU]/mL) on a sputum culture was consid-
ered a presumptive pathogen. Moderate growth (105 or 106 CFU/
mL) on the sputum culture was also considered a presumptive
pathogen if the Gram staining was compatible with the culture
results. Streptococcus pneumoniae and Legionella pneumophila
serogroup 1 were detected using the Binax NOW® rapid immuno-
chromatographic assay (Binax Inc., Portland, ME, U.S.A.). Myco-
plasma pneumoniae was detected by culturing sputum samples or
pharyngeal swabs in a pleuropneumonia-like organism medium
and/or by the protective antigen method. Chlamydophilapneumoniaewas detected by enzyme-linked immunosorbent assay.
Standard serological methods using single or paired sera were
applied to determine whether there was elevation of antibodies
against M. pneumoniae (a single increase  320 or a fourfold in-
crease in paired sera) and C. pneumoniae (a single increase up
to  3.0 as the cut-off index or a 1.3 cut-off index increase in
paired sera). When multiple pathogens satisﬁed the above criteria
in one patient, the pneumonia was deﬁned as polymicrobial. MRSA
was deﬁned with a minimum inhibitory concentration4 mg/mL to
oxacillin. ESBL-positive Enterobacteriaceae was deﬁned by obser-
vation of resistance to oxymino-b-lactam substances and inhibition
by clavulanic acid.2.3. Statistical analysis
The data were analyzed using the Statistical Analysis System®
software program version 9.3 (SAS institute Inc., Cary, NC, U.S.A.).
The chi-square test was used to compare categorical data, and
Fisher's exact test was used when there were less than 10 data
points for any parameter. The unpaired Student's t-test or the
ManneWhitney U test was used for continuous data to compare
the two groups. A P value < 0.05 was considered statistically
signiﬁcant.
The risk factors for infection with PES pathogens were analyzed
using a logistic regression model. All of the variables with P < 0.25
in the univariate analysis were included to construct the multi-
variate analysis. Odds ratios and 95% CIs were calculated.
We determined the area under the receiver-operating charac-
teristic (ROC) curve for the risk factors deﬁned by the multivariate
logistic regression to predict PES pathogens.3. Results
3.1. Patient characteristics
During the study period, 1559 patients were assessed, and an
etiological diagnosis was determined in 705 patients. Of those, 170
patients met the criteria for healthcare-associated pneumonia
(HCAP). The baseline patient characteristics of the PES pathogen
group and the non-PES pathogen group are shown in Table 1. The
patients with PES pathogens were older than the non-PES patients
and had a lower frequency of male sex and smoking history but a
higher frequency of hospital discharge within 30 days, bronchiec-
tasis, enteral feeding, and poor performance status (PS3 or 4).
Baseline clinical ﬁndings at admission are shown in Table 2. The
rates of orientation disturbance, low blood pressure, and hypox-
emia were not signiﬁcantly different between the two groups.
Laboratory ﬁndings showed a high frequency of anemia in the PES
patients. Bacteremia was recognized in 6 PES patients and in 56
non-PES patients, revealing no signiﬁcant difference in frequency.3.2. Pathogen distribution
The organisms isolated in 705 patients are shown in Table 3.
Streptococcus pneumoniae was the most common pathogen. A
polymicrobial etiology was detected in 108 patients (15.3%). A total
of 51 patients (7.2%) presented with pneumonia due to PES path-
ogens, and 53 PES pathogenswere isolated (P. aeruginosa: 34; ESBL-
positive Klebsiella pneumoniae: 3; ESBL-positive Escherichia coli: 3;
and MRSA: 13). Two patients presented with dual PES pathogens
(P. aeruginosa þ MRSA; K. pneumoniae þ MRSA). In the PES group,
27 patients (52.9%) met the criteria for HCAP.
Table 1
Baseline characteristics of patients with PES vs. non-PES pathogens.
Variables PES (n ¼ 51) Non-PES (n ¼ 654) P value
Age 78.8 ± 13.4 74.5 ± 14.7 0.165
Gender, male, n% 26 (51.0%) 437 (66.8%) 0.021
Smoking history 21 (41.2%) 383 (58.6%) 0.015
Alcohol abuse 0 (0%) 22 (3.4%) 0.183
Nursing home resident 7 (13.7%) 61 (9.3%) 0.305
Hospital discharge within 30 days 18 (35.3%) 113 (17.3) 0.001
Matched with HCAP criteria 27 (52.9%) 143 (21.9%) 0.188
Previous antibiotic treatment, n% 16 (31.4%) 134 (20.5%) 0.067
Comorbidity
Congestive heart failure, n% 21 (32.1%) 211 (32.3%) 0.192
Chronic obstructive pulmonary disease, n% 11 (21.6%) 153 (23.4%) 0.766
Bronchiectasis, n% 8 (15.7%) 21 (3.2%) <0.001
Chronic liver disease, n% 4 (7.8%) 31 (4.7%) 0.326
Chronic kidney disease, n% 6 (11.8%) 61 (9.3%) 0.568
Cerebrovascular disease, n% 15 (22.9%) 145 (22.2%) 0.234
Diabetes, n% 7 (13.7%) 118 (18.0%) 0.437
Enteral feeding 10 (19.6%) 15 (2.3%) <0.001
Poor performance status (3e4), n% 25 (49.0%) 123 (18.8%) <0.001
Table 2
Clinical ﬁndings of patients with PES pathogens vs. non-PES pathogens at admission.
Variables PES (n ¼ 51) Non-PES (n ¼ 654) P value
Orientation disturbance, n % 14 (27.5%) 142 (21.7%) 0.342
Systolic BP < 90, n % 5 (9.8%) 34 (5.2%) 0.166
PaO2/FiO2 ratio < 250, n % 17 (33.3%) 270 (41.2%) 0.266
Laboratory ﬁndings
BUN  21 mg/dL, n% 20 (39.2%) 320 (48.9%) 0.181
Na < 130 mEq/dL, n% 6 (11.8%) 43 (6.6%) 0.160
Glucose  250 mg/dL, n% 3 (5.9%) 51 (7.8%) 0.620
Hematocrit < 30%, n% 13 (19.6%) 71 (10.9%) 0.002
Bacteremia 6 (11.8%) 56 (8.6%) 0.437
PSI (pneumonia severity index) 117 ± 34.9 110 ± 39.4 0.102
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All of the patients underwent empirical antimicrobial treatment
at the time of admission in accordance with the pneumonia
guidelines of the Japanese Respiratory Society [7,8]. Among the PES
patients, penicillin with a beta-lactamase inhibitor was most oftenTable 3
Microbiological results.
Organism n (%)
Streptococcus pneumoniae 319 (45.2%)
Streptococcus anginosus group 41 (5.8%)
Other streptococcus 29 (4.1%)
MSSAa 50 (7.1%)
MRSAb 13 (1.8%)
Moraxella catarrhalis 41 (5.8%)
Haemophilus inﬂuenzae 88 (12.5%)
Klebsiella pneumoniae 40 (5.7%)
ESBLþ 3
Escherichia coli 16 (2.3%)
ESBLþ 3
Pseudomonas aeruginosa 34 (4.8%)
Other Enterobacteriaceae 9 (1.3%)
Mycoplasma pneumoniae 18 (2.6%)
Chlamydophila pneumoniae 52 (7.4%)
Chlamydophila psittaci 3 (0.4%)
Legionella spp. 20 (2.8%)
Anaerobes 24 (3.4%)
Inﬂuenza virus 6 (0.9%)
Other organisms 12 (1.7%)
Polymicrobial 108 (15.3%)
a Methicillin-susceptible Staphylococcus aureus.
b Methicillin-resistant Staphylococcus aureus.used, in 36 patients (70.6%). Combination therapy was used in 8
patients (15.7%). Seventeen patients (33.3%) received antimicro-
bials that covered PES pathogens. Second-line antimicrobials were
changed or added to the ﬁrst-line choices based upon culture re-
sults or clinical efﬁcacy in 23 PES patients (45.1%). The mortality
rates of patients who received adequate therapy and those who did
not receive such treatment were 5.9% and 8.8%, respectively, which
revealed no signiﬁcant difference (P ¼ 0.854).
3.4. Clinical outcomes
Table 4 details the clinical outcomes in both groups. The rate of
initial treatment failurewas higher in the PES group (P¼ 0.010), but
30-day mortality was not signiﬁcantly different (P ¼ 0.487). The
PES group had a higher rate of re-admission within 30 days
(P ¼ 0.009) and a longer hospital stay (P < 0.001).
3.5. Risk factors for PES pathogens
By univariate analysis, 10 variables revealed a P value < 0.25 and
were included to construct the multivariate analysis. The following
four variables were thought to be independent predictors of
infection with PES pathogens (Table 5): female sex (AOR 1.998, 95%
CI 1.047e3.810, P ¼ 0.036); admission within 90 days (AOR 2.827,
95%CI 1.250e6.397, P ¼ 0.013); poor performance status (PS 3 or 4)
(AOR 2.380, 95%CI 1.047e5.413, P ¼ 0.039); and enteral feeding
(AOR 5.808, 95%CI 1.813e18.613, P ¼ 0.003).
Fig. 1 shows the ROC curves for counting numbers of the four
risk factors and for the PES scores of our patients as proposed by
Prina and colleagues, based on the following seven risk factors for
PES pathogens: age 65 years or older, male sex, previous antibiotic
use, chronic respiratory disease, kidney disease, altered mental
status, or temperature over 37.8 C. The areas under the curve
(AUC) for our variables were 0.660 (95% CI 0.577e0.744) and 0.606
(95% CI 0.524e0.678) which reﬂects the PES score.
4. Discussion
Recently, many investigations have been undertaken to explore
the risk factors for pneumonia due to drug-resistant pathogens.
However, each study has pointed to different pathogens as being
drug resistant. For example, Shorr and colleagues deﬁned MRSA,
P. aeruginosa, and ESBL-producing Enterobacteriaceae as resistant
pathogens and developed a scoring system using the following
Table 4
Clinical outcomes in patients with PES pathogens and non-PES pathogens.
Variables PES (n ¼ 51) Non-PES (n ¼ 654) P value
ICU admission, n (%) 3 (5.9%) 51 (7.8%) 0.620
Initial treatment failurea, n (%) 12 (23.5%) 74 (11.3%) 0.010
30 days mortality, n (%) 4 (5.7%) 36 (5.5%) 0.487
Re-admission within 30 days, n (%) 5 (9.8%) 19 (2.9%) 0.009
Length of hospital stay, days 15.0 ± 9.9 12.8 ± 3.5 <0.001
a Death during the initial treatment or a change to other antimicrobials due to a lack of response to the initial ones.
Table 5
Multivariate logistic regression for risk factors for infection with PES pathogens.
variables Adjusted odds ratio 95% conﬁdential interval P value
Female sex 1.998 1.047e3.810 0.036
Previous antimicrobial use 1.689 0.829e3.438 0.149
Fever < 37.8 C 0.642 0.335e1.230 0.181
Admission within 90 days 2.827 1.250e6.397 0.013
Hemodialysis 1.736 0.200e15.102 0.617
Poor performance status (3, 4) 2.380 1.047e5.413 0.039
Presence of aspiration 0.896 0.412e1.949 0.782
Chronic heart disease 1.248 0.641e2.427 0.514
Cerebrovascular disease 0.661 0.278e1.568 0.347
Tube feeding 5.808 1.813e18.613 0.003
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admission, and hemodialysis [9]. Aliberti and colleagues deﬁned
MRSA, multidrug-resistant P. aeruginosa, Stenotrophomonas malto-
philia, vancomycin-resistant Enterococcus, Acinetobacter baumannii,
and ESBL-producing Enterobacteriaceae as multidrug-resistant or-
ganisms, and created another scoring system using the following
risk factors: chronic renal failure, recent hospitalization, nursing
home residency, cerebrovascular disease, diabetes, chronic






















Fig. 1. Receiver operating characteristics (ROC) curve for prediction of PES pathogens.
Four risk factors were as follows: female sex, admission within 90 days, poor perfor-
mance status (3 and 4), and enteral feeding. PES score was calculated as the sum of the
following score: age 40e65, 1; >65, 2; male sex, 1; previous antibiotic use, 2; chronic
respiratory disorder, 2; chronic renal disease, 3; consciousness impairment, 2; and
fever > 37.8 C, -1.immunosuppression, home wound care, and home infusion ther-
apy [10,11]. Shindo and colleagues deﬁnedMRSA, P. aeruginosa, and
ESBL-producing Enterobacteriaceae as CAP resistant pathogens, and
listed six risk factors: prior hospitalization, immunosuppression,
previous antibiotic use, use of gastric acid-suppressive agents,
enteral feeding, and non-ambulatory status and showed that a
counting method of these factors was more sensitive in the
detection of MDR pathogens than the two scores describe above
[12]. Maruyama and colleagues deﬁned MRSA, P. aeruginosa, A.
baumannii, ESBL-producing Enterobacteriaceae as drug resistant
and analyzed patients with healthcare-associated pneumonia using
the following risk factors based on the deﬁnition of Brito and col-
leagues [13]: recent antibiotics, recent hospitalization, poor func-
tional status, and immunosuppression [14]. However, the subjects
of these studies also included HCAP patients with an immuno-
compromised status.
Recently, there have been many opinions criticizing the concept
of HCAP in Europe. They include the following: the deﬁnition of
HCAP could lead to overtreatment; the concept of HCAP cannot
deﬁne resistant pathogens accurately; and the deﬁnition includes
immunocompromised patients [2,3,15,16]. On the other hand, it has
been reported that the poor outcomes in HCAP patients were not
inﬂuenced by resistant pathogens or by selection of antimicrobials,
but rather, were related to the general status of the patients
including their comorbidities [17e20]. Thus, it is thought to be
necessary to analyze risks for drug-resistant pathogens in immu-
nocompetent patients. There have been few studies examining risk
factors in only CAP patients. Recently, Torres and colleagues studied
CAP cases with bacteremia and listed the risk factors for antibiotic-
resistant pathogens (multidrug-resistant Streptococcus pneumo-
niae, MRSA, P. aeruginosa, and ESBL-producing Enterobacteriaceae)
as follows: prior antibiotic treatment, C-reactive protein <22.2 mg/
dL, and absence of pleuritic pain [21]. Recent studies have reported
that there was no difference in etiology between HCAP and CAP
[19,22,23] when subjects were immunocompetent. Therefore, CAP
patients and HCAP patients who were thought to be immuno-
competent were enrolled into our study. We regarded PES patho-
gens as drug-resistant pathogens in this population.
In our study, the frequency of PES pathogens in immunocom-
petent patients with pneumonia was not very high (7.5%), and the
T. Ishida et al. / J Infect Chemother 23 (2017) 23e28 27frequency of each PES pathogen was similar to those in Prina's
study. Speciﬁcally, we detected only a few cases of pneumonia due
to ESBL-producing Enterobacteriaceae. However, drug-resistant
pathogens other than PES were seldom recognized in this study.
Thus, it might be appropriate in immunocompetent patients to
deﬁne PES pathogens as drug-resistant organisms for which com-
mon antimicrobials for CAP are ineffective.
Prina and colleagues reported that PES pathogens were inde-
pendently associated with 30-day mortality. On the other hand,
therewas no differencewith regard to the severity of pneumonia or
30-day mortality between the PES group and the non-PES group in
our population. However, the increases in initial treatment failures,
re-admission rates, and prolongation of hospital stays were
recognized in PES patients, indicate that pneumonia due to PES
pathogens is thought to be refractory.
Risk factors for PES pathogens analyzed in our multivariate
analysis showed considerable differences compared with those
in Prina's previous study. Female sex was dominant, while age
was not a signiﬁcant factor in our patients. Comorbidities and
previous use of antimicrobials were also not signiﬁcant, while
recent hospitalization was a risk factor. It is worthy of note that,
in our results, poor performance status was an independent risk
factor. More than half of our PES patients satisﬁed the criteria for
HCAP. Patients who are immunocompetent but who have poor
general status, along with patients undergoing enteral feeding,
are thought to be susceptible to PES infection. It is known that
aspiration is highly associated with HCAP, especially in patients
with poor performance status [24,25]. Many patients with
aspiration pneumonia experience recurrent pneumonia and
undergo repeated antimicrobial treatments, which leads to
infection due to PES pathogens. When we previously investi-
gated the clinical ﬁndings of pneumonia in bedridden patients
(PS 3 and 4), 6.9% of the cases were due to PES pathogens [26].
These ﬁndings seemed to depend on the differences between
targeted subjects in both studies. Our study and Prina's are both
single-center cohorts, which might reﬂect the characteristics of
the individual institutions. We experienced many elderly pa-
tients (average age: 74.8 years), reﬂecting the aging society in
Japan, who exhibited poor performance status. However, the
AUCs of both our study and the PES score are quite low. So, we
have to do further analysis about the risk factors of drug-
resistant pathogens.
Our study had several limitations. First, as mentioned above,
this was a single-center study and may have a population bias.
Second, there is a possibility that patients were colonized with
PES pathogens and that they might not have been the causative
agents of pneumonia, even though they were detected in large
quantities. We deﬁned strict microbiological criteria in deciding
the etiology. However, we often found it difﬁcult to conclude that
the detected pathogens were the causative agents in HCAP pa-
tients [27]. It was reported that recurrent airway infections led to
colonization with P. aeruginosa or MRSA in the lower respiratory
tract [28]. Third, the frequency of PES pathogens, especially ESBL-
producing Enterobacteriaceae was relatively low in immuno-
competent populations, thus we could not analyze the risks for
each pathogen separately. Fourth, we could not analyze the in-
ﬂuence of previously prescribed antimicrobials because we did
not have details of the exact medications prescribed by previous
doctors.
In conclusion, we believe it is appropriate to deﬁne PES patho-
gens as drug resistant in immunocompetent patients. Pneumonia
due to PES pathogens is refractory, though the frequency is low.
Caution is required in the treatment of pneumonia caused by PES
pathogens, especially in patients with poor performance status or
enteral feeding.Conﬂict of interest
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